The firm - who we are:

The firm`s founder, Dipl. Natw. (Chem.) ETH, Dr.sc.nat. ETH, Gilles  Reiss(-Hürlimann), *1968, spent more than 10 years working  as a patent attorney in chemical industry in Switzerland and Germany (2000-2007 Lonza AG, Basel/CH, 2007-2011 Basell Polyolefins GmbH, Frankfurt Main/Germany,  part of Lyondell Basell Industries). Both workplaces were big corporations with annual sales in excess of 1 billion, pursuing a truly international perspective in obtaining patents in  a large number of countries, worldwide,  whilst Dr. Reiss kept directly representing  his corporate client in all EPO proceedings including opposition and in particular in oral appeal proceedings at teh EPO (cp. Lyondell Basell Industries) .   Beside regular drafting and prosecution work, he advised on secrecy and license contracts  as well as on know how disputes, patent enforcement & litigation/freedom to operate.

 Supplementarily, you may browse the profile of Dr. Reiss-Hürlimann on Linkedin.com or refer to our Swiss Office page for more information.

 

Case law references

*=represented patentee, otherwise opponent

 

1. EPO, successful board of appeal cases (inter partes cases only, i.e. final instance  court in opposition cases, deciding on nullity of granted EP patent, non-appealable)

 

Borealis EP-1187876

Exxon    EP-977786

Basell    EP-986610*

Basell    EP-1228101 *

BorealisEP-1333044 (Borealis offered to settle  Jan. 11, prior to oral trial in Feb..)

Chiron   EP-435911

Borealis EP-1095102

Borealis EP-1204523  

Borealis EP-1159350

Basell EP-791609*

 

 

2. EPO, opposition division (1st instance nullity cases at the EPO)

 

ISIS Pharm.EP1023310

Genentech EP1084136

ChevronPhilips EP1749 060 

Borealis EP-1204523

Borealis EP-1333044

Glaxo EP-504 363

Basell EP-1141118*

Basell EP-1008628*

Basell EP-1228101*

Basell EP-1572755*

Basell EP-1675899*

Basell EP-1204685*

Basell EP-1675899*

Borealis EP-1084162

LaJolla Cancer Research EP-751709

 

 

 

3. Drafting / prosecution (selection; note: where *, only prosecution)

 

EP-2239283 B (filed: Nov. 2009/ R.71.3 com. issued 2011)

  BASELL POLYOLEFINE GmbH

Novel LDPE from high pressure tubular reactor,  for medical use/blow-fill-seal sterile products such as infusion bags, allowing ofshortened sterilization treatment.

- opposition period not yet expired

 

WO 2009/103516 Basell Polyolefine GmbH,

PE coating for steel pipes and other purposes, cable sheating, rotomoulding(Rotomoulding appliance continuted in WO 2011-/020622, -621, 620 ).

- granted EP Patent now opposed by Borealis (Aug. 2012)

 

 

   .  
  (WO 2011/000497) POLYETHYLENE MOULDING COMPOSITION 
  06.01.2011   
    
    
  BASELL POLYOLEFINE  GMBH  
 


     
  A novel polyethylene composition is described. The composition  is suitable for manufacturing especially stretched bands or tapes, also  coined raffia in the art.  
 






    
    
 






  .  
  (WO 2010/063432) PROCESS FOR THE POLYMERIZATION OF  ETHYLENE, AND ETHYLENE POLYMERS HAVING BROAD MOLECULAR WEIGHT DISTRIBUTION  AND LONG- CHAIN BRANCHING 
  10.06.2010   
    
    
  BASELL POLYOLEFINE GMBH   
    
    
 
     
  New  ethylene polymers having broad molecular weight distribution and long-chain  branching, above all at high molecular weight fractions; the polymers have  strain hardening equal or higher than 1.4 (at constant elongational rate of  0.5s-1, at 150°C), branching index g'  equal or lower than 0.9 (at Mw of 210exp6 g/mol).  The polymers are prepared by using a mixed catalyst system comprising a  polymerization catalyst based on a late transition metal component having a  tridentate ligand, and a Ziegler polymerization catalyst annealed at a  temperature higher than 100°C, for a time of at least 10 minutes.     
 






  17.  
  (WO 2010/034520) IMPACT RESISTANT LLDPE COMPOSITION AND  FILMS MADE THEREOF 
  01.04.2010  
    
    
  BASELL POLYOLEFINE GMBH   
 


     
  A novel PE material is devised showing excellent  mechanical/optical properties and process ability, e.g. for film extrusion.  The polyethylene of the invention is produced in one single e.g. gas phase  reactor.  
 






     
    







  18.  
  (WO 2010/034508) IMPACT RESISTANT LLDPE COMPOSITION AND  FILMS MADE THEREOF     Dito, s. No. 17 above     
  01.04.2010   
    
    
  BASELL POLYOLEFINE GMBH   
    
    

     
  (WO 2010/139419) POLYETHYLENE COMPOSITION AND FINISHED  PRODUCTS MADE THEREOF 
  09.12.2010  
    
    
  BASELL POLYOLEFINE  GMBH  
 


    
  Novel polyethylenes having defined molecular weight distribution  and LCB structure are devised, for films or mouldings.  







 

 

(WO 2008/019798) A PROCESS FOR THEPREPARATION OF LAMOTRIGINE (3,5-Diamino-6-(2,3-dichlorphenyl)- 1,2,4-triazin)

 (note:  PRIORITY APPLICATIONS drafted & filed by G. Reiss; PCT was filed after leave from Lonza)

21.02.2008

C07D 253/075

PCT/EP2007/007055

LONZA AG

 

A novel process for the preparation of lamotrigine (3,5-Diamino-6-(2,3-dichlorphenyl)- 1,2,4-triazin), an active pharmaceutical ingredient,  and its intermediates is devised, using sulfonic acid both as a solvent and acidifier.

 

 

(WO 2007/093368) REDUCTION OF5-(ARYL-DIAZENYL)-4,6-DIHALO-PYRIMIDINE

23.08.2007

C07D239/42

PCT/EP2007/001216

LONZAAG

 

Methodof synthesizing a compound of formula (I), wherein Rl, R2 are, independently,chloro or fluoro, and wherein R3 is H, alkyl, aralkyl or is an alkylether oralkylthioether comprising the steps of firstly reducing a diazeny compound offormula (II) non-catalytically or with a catalytic amount of an homogenousorganic, non-metal catalyst to the corresponding hydrazo compound of formula(III) and in a second step catalytically hydrogenating said hydrazo compound inwith a heterogeneous Ni-catalyst to the compound of formula (I).

 

 

(WO 2007/090496) SYNTHESIS OF GLUCAGON-LIKE PEPTIDE

16.08.2007

C07K1/10

PCT/EP2007/000198

LONZAAG

 

Anew method of synthesizing GLP-1 peptide is devised.

 

 

(WO 2006/117227)SOLID PHASE BOUND THYMOSIN ALPHA-1 AND ITS SYNTHESIS

09.11.2006

C07K14/575

LONZAAG

 

Amethod for the solid phase peptide synthesis of thymosin alpha-1 is disclosed.The peptide or fragments thereof are synthesised on a polyethylene glycol (PEG)resin. The method provides high yields and pure products.

 

 

(WO 2006/045603)S-ALKYL-SULPHENYL PROTECTION GROUPS IN SOLID-PHASE SYNTHESIS

04.05.2006

C07K1/06

LONZAAG

 

Anovel method for on-resin, disulfide-borne cyclization of peptides is devised.

 

 

(WO 2006/045483)ON-RESIN PEPTIDE CYCLIZATION

04.05.2006

C07K1/06

LONZAAG

 

Methodof peptide synthesis, comprising the steps of a. synthesizing a peptide linkedto a solid phase which peptide comprises at least one cysteine, homo- ornor-cysteine residue, which cysteine is protected in its side chain by aS-tert.butyl-sulphenyl group b. either coupling N-terminally a further aminoacid having a 3,3'-dithio-(1--carboxy-propyl)-propionyl-radical on its Nα ordeprotecting the Nα of the N-terminal amino acid and reacting the free Nα with3,3'-dithio-propionic acid imide to yield the correspondingNα-3,3'-dithio-(1-carboxy-propyl)--propionamide or deprotecting the Nα of theN-terminal amino acid and reacting the free Nα with a compound of formula IVR7-S-S-[CH2]2-COOH IV wherein R7 is ar...

 

(WO 2006/032457) PEPTIDE CYCLISATION

30.03.2006

C07K 1/06

LONZA AG

 A novel method for side chain cyclisation ofpeptides by means of lactamization is provided, as shown on the example ofbremelanotide (PT-41) derivatives . – Opposedby Novo Nordisk

  

(WO 2006/008050)METHOD OF PEPTIDE SYNTHESIS

26.01.2006

C07C231/02

LONZAAG

 

Anovel method for amidation of C-terminal carboxyl groups of peptides isdevised, which methods avoids undesired epimerisation of the α-carbon of theC-terminal amino acid yielding diastereoisomeric variants of the amidatedpeptide.

 

 

WO(2004/076485) Lonza Biologics – Chromatography method for purifying therapeutic antibodies.

 Inventors: Julian Bonnerjea & Anna Preneta – opposed by not less than 6 competitor companies at the European Office, after grant! –also cp.above the opposition brief drafted against chromatography patents of  Genentech & Glaxo

 

 

WO 2009/103516 , PE coating for steel pipes(Rotomoulding Anwendung ist in WO 2011-/020622, -621, 620 weitergeführtworden)

 

WO 2010/025918  Trimodales Ziegler-PE(Hostalen) mit PB-1 for piping (priority application, PCT filed & handled by a colleague)

 

 

EP-1379676 (WO02/074737) – Process for the preparation of 2-Hydroxymethyl-Pyrrolidine-3,4-Diols

 A process for thepreparation of 2-hydroxymethyl-pyrrolidine-3,4-diols of the formulae comprisingthe steps of a) biooxidation of N-protected aminotetraols of the formula b)deprotection of the corresponding N-protected 5-amino-5-deoxy-pentulose c)hydrogenation of the corresponding 5-amino-5-deoxy-pentulose.

 

4. Varia (e.g. appeal brief in US prosecution, body of argument adopted unamended by US colleague)

 

Instructed prosecution  and provided draft appeal brief on material patentability/lack of primafacie obviousness for ex parte appeal of USSN 09/867552

PROCESS FOR THE PREPARATION OF N-(AMINO-4, 6-DIHALO-  PYRIMIDINE)- FORMAMIDES (Saikali et al.) by phase transfer catalysis

including(at prosecution or appeal stage) an 1.131 affidavit signed by inventor, outlining and corroborating the  technical merits in support of our non-obviousness argument.